CD19 and acute lymphoblastic leukemia: CD19 CAR-T-cell primary resistance occurs in 10–20% of ALL patients; in a Philadelphia Children’s Hospital trial, 20 of 55 ALL patients experienced recurrence, 13 (24%) of whom were CD19 negative (73).